Page last updated: 2024-08-25

bexarotene and Lymphoma, T-Cell, Cutaneous

bexarotene has been researched along with Lymphoma, T-Cell, Cutaneous in 97 studies

Research

Studies (97)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.03)	18.2507
2000's	51 (52.58)	29.6817
2010's	31 (31.96)	24.3611
2020's	14 (14.43)	2.80

Authors

Authors	Studies
Darwaiz, T; Deans, DG; Grozic, A; Heck, MC; Jurutka, PW; Ma, N; MacNeill, M; Marshall, PA; Robinson, NM; Salama, SH; Shahani, PH; Shimabuku, M; van der Vaart, A; Wagner, CE; Ziller, JW	1
Eich, HT; Elsayad, K; Livingstone, E; Moritz, RKC; Müller, EC; Nawar, T; Rolf, D; Stadler, R; Steinbrink, K; Stranzenbach, R; Sunderkötter, C; Weishaupt, C	1
D'Incan, M; Joulie, I; Lambert, C; Rouanet, J	1
Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N	1
Aquino, C; Avallone, G; Boskovic, S; Fava, P; Macagno, N; Quaglino, P; Ribero, S; Roccuzzo, G	1
Ardigò, M; Cicini, MP; Franceschini, C; Mandel, VD; Saraceni, PL; Teoli, M	1
di Martino, O; Ivan, DJ; Jurutka, PW; Khadka, I; Krall, TD; Le, A; Lee, IJ; Lee, MY; Liu, W; Mallick, S; Marshall, PA; Moen, GA; Noh, Y; Peoples, SJ; Perez, A; Petros, R; Reshi, S; Salama, E; Salama, J; Sausedo, MA; Savage, BM; Tromba, L; Wagner, CE; Welch, JS; Ziller, JW	1
Fukumoto, T; Imamura, S; Itoh, T; Kubo, A; Nakamura, K; Nakano, E; Nishigori, C; Tanaka, T; Tanigawa, A	1
Elsea, D; Lilley, C; Lisano, J; Liu, J; Savage, KJ; Yu, KS	1
Applegate, MT; Haddad, D; Jurutka, PW; Khamisi, M; Livingston, S; Marshall, PA; Reshi, S; Ron, E; Sabir, Z; Sausedo, M; Staniszewski, LJP; Wagner, CE; Warda, A	1
Kato, H; Kubo, R; Morita, A; Muramatsu, S; Nishida, E; Tateishi, C; Tsuruta, D; Yonezawa, E	1
Aiba, S; Amagai, R; Fujimura, T; Fujisawa, Y; Fukushima, S; Kambayashi, Y; Miyashita, A; Ogata, D; Sato, Y; Shimauchi, T; Tanita, K	1
Zic, JA	1
Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S	1
Einar French, L; Guertler, A; Helene Frommherz, L; Kaemmerer, T; Reinholz, M; Stadler, PC	1
Eshagh, K; Romero, LS; So, JK; Zhao, XF	1
Bridges, LC; Chen, J; Crouch, MJ; DeMarco, SS; Maiorana-Boutilier, AL; Peaks, MS; Phillips, CM; Shaikh, SR; Shewchuk, BM; Wang, L	1
Geskin, L; Malone, DC	1
Atigadda, VR; Chang, PL; Chou, CF; Dummer, R; Elmets, CA; Eto, I; Garvey, WT; Grubbs, CJ; Hsieh, YH; Mobley, JA; Muccio, DD	1
Alia, P; Cabello, I; Cervigón, I; Estrach, T; Fernandez-de-Misa, R; Gallardo, F; Izu, R; Morillo, M; Muniesa, C; Ortiz-Brugues, A; Ortiz-Romero, PL; Peñate, Y; Perez-Farriols, A; Pintó, X; Román, C; Servitje, O	1
Astrua, C; Fava, P; Fuligni, F; Grandi, V; Guglielmo, A; Gunnella, S; Patrizi, A; Pileri, A; Pimpinelli, N; Quaglino, P; Simontacchi, G	1
Delfino, C; Grandi, V; Pileri, A; Pimpinelli, N	1
Brocard, A; Dréno, B; Knol, AC; Peuvrel, L; Quéreux, G; Saint-Jean, M	1
Chan, C; Counsell, N; Cowan, R; Gilson, D; Illidge, T; Morris, S; Patrick, P; Popova, B; Scarisbrick, J; Smith, P; Whittaker, S	1
Duvic, M; Feldman, T; Goy, A; Hernandez-Ilizaliturri, FJ; Horwitz, SM; Hymes, K; Myskowski, PL; Straus, DJ; Wegner, B	1
Dalle, S; Graeppi-Dulac, J; Orgiazzi, J; Perier-Muzet, M; Vlaeminck-Guillem, V	1
González-Morán, A; Otero-Rivas, MM; Rodríguez-Prieto, MÁ; Sánchez-Sambucety, P	1
Craig, FE; Grandinetti, LM; Ho, J; Jedrych, J; Johnson, WT; Leeman-Neill, RJ; Patel, P	1
Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O	1
Berger, CL; Edelson, RL; Girardi, M; Heald, P	1
Fleischer, AB; Kannangara, AP; Levitan, D	1
Apraiz, A; Asumendi, A; Boyano, MD; Díaz-Pérez, JL; Izu, R; Nieto-Rementería, N; Pérez-Yarza, G	1
Horwitz, SM	1
Ardizzoni, A; Di Nuzzo, S; Musolino, A; Panebianco, M; Santini, M; Zendri, E	1
Tronnier, M	1
Ballanger, F; Brocard, A; Dréno, B; Khammari, A; Knol, AC; Nguyen, JM; Quéreux, G	2
Anand, D; Gormley, RH; Hess, SD; Junkins-Hopkins, J; Kim, EJ; Rook, AH	1
Ballanger, F; Dréno, B; Khammari, A; Nguyen, JM	1
Bosenberg, MW; Carlson, KR; Girardi, M; Kreizenbeck, GM; Muthusamy, V; Trufant, JW	1
Krohn, K; Ranki, A; Sipilä, L; Väkevä, L	1
Battistella, M; Sassolas, B	1
Chemnitz, J; Kurschat, P; Scheid, C; Schlaak, M; Shimabukuro-Vornhagen, A; Stadler, R; Theurich, S; von Bergwelt-Baildon, M	1
Alvarado, CS; Busam, KJ; Hale, GA; Horwitz, S; Jaffe, ES; Kim, YH; Mehta, N; Myskowski, P; Pulitzer, M; Wayne, AS; Zwerner, J	1
Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ	1
Schmidt, C	1
Hahtola, S; Ranki, A; Väkevä, L	1
Cheeley, J; DeLong, LK; Parker, SR; Sahn, RE	1
Baso, JC; Bhogal, JS; Browder, DO; Furmick, JK; Gray, GM; Groy, TL; Huynh, CC; Jurutka, PW; Kaneko, I; Kwon, JS; Lemming, B; Marcus, LM; Marshall, PA; Montano, LA; Prentice, JL; Quezada, A; Reyes, NM; Saini, P; Tsosie, DG; van der Vaart, A; Wagner, CE; Walsh, AN; Yang, J	1
Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS	1
Alterini, R; Canafoglia, L; Delfino, C; Goteri, G; Grandi, V; Pileri, A; Pimpinelli, N; Quaglino, P; Rupoli, S	1
Kerdel, FA; Romanelli, P; Trent, JT	1
French, LE; Junkins-Hopkins, JM; Lehrer, MS; Rook, AH; Shapiro, M; Vittorio, CC	2
Budgin, JB; Everitts, S; Junkins-Hopkins, JM; McGinnis, KS; Richardson, SK; Rook, AH; Vittorio, CC; Wysocka, M	1
Sherman, SI	1
Martin, AG	1
Crowley, CA; Heald, P; Martin, AG; Mehlmauer, M; Reich, SD; Yocum, RC	1
Farol, LT; Hymes, KB	1
Fung, BB; Guitart, J; Kuzel, TM; Posten, W; Querfeld, C; Rademaker, A; Rosen, ST	1
Whitmore, SE	1
Lebwohl, MG; Singh, F	1
Demierre, MF; DiVenuti, G; Foss, F	1
Barnouin, R; Calleja, C; Cantiello, M; Concordet, D; Gauthier, B; Lasserre, F; Martin, PG; Pineau, T; Roulet, A; Van Es, A	1
Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W	1
Alencar, AJ; Apisarnthanarax, N; Duvic, M; Herne, KL; Jones, DM; Talpur, R; Yang, Y	1
Acebo, E; Díaz-Pérez, JL; Eguino, P; Izu, R; Lasa, O	1
Guitart, J	1
Cerroni, L; French, LE; Kerl, K; Prins, C	1
Altmeyer, P; Gambichler, T; Kreuter, A	1
Burg, G; Dummer, R; Hauschild, A; Skalsky, J; Weichenthal, M	1
Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S	2
Greer, JP; Koyama, T; Sepmeyer, JA; Zic, JA	1
Demierre, MF; Duvic, M; Horwitz, S; Kuzel, T; Myskowski, P; Steckel, S; Straus, DJ	1
Hymes, KB	1
Stadler, R	1
Demierre, MF; Ferzli, P; Miller, D	1
Assaf, C; Bagot, M; Dummer, R; Gniadecki, R; Hauschild, A; Knobler, R; Ranki, A; Stadler, R; Whittaker, S	1
Scheinfeld, N	1
Avilés Pérez, MD; de Argila Fernández-Durán, D; Díaz Pérez de Madrid, J; Luna López, V; Rodríguez Nevado, I	1
Aldaoud, A	1
Gniadecki, R; Kamstrup, M	1
Chiu, AC; Duvic, M; Gopal, J; Haugen, BR; Nowlakha, P; Sherman, SI; Whaley, K	1
Henney, JE	1
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA	1
Baker, C; Davison, J; McCormack, C; Prince, HM; Rotstein, H; Ryan, G; Yocum, R	1
Duvic, M	2
Breneman, D; Crowley, C; Duvic, M; Heald, P; Hymes, K; Martin, AG; Myskowski, P; Yocum, RC	1
Wong, SF	1
LeMaistre, CF	1
Heald, P	1
French, LE; Junkins-Hopkins, JM; Rook, AH; Shapiro, M; Vittorio, CC	1
Duvic, M; Hazarika, P; Ni, X; Weidner, DA; Zhang, C	1

Reviews

22 review(s) available for bexarotene and Lymphoma, T-Cell, Cutaneous

Article	Year
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma. The Medical clinics of North America, 2021, Volume: 105, Issue:4 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms	2021
Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. Immunotherapy, 2013, Volume: 5, Issue:4 Topics: Anticarcinogenic Agents; Bexarotene; Drug Delivery Systems; Humans; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Tetrahydronaphthalenes	2013
Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. European journal of endocrinology, 2014, Volume: 170, Issue:6 Topics: Aged; Antineoplastic Agents; Bexarotene; Endocrine System Diseases; Female; Gene Expression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Thyroid Gland; Thyrotropin; Thyrotropin, beta Subunit	2014
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2008, Volume: 143, Issue:1 Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Clone Cells; Cytokines; Dendritic Cells; Diphtheria Toxin; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mice; Neoplastic Stem Cells; Photopheresis; PUVA Therapy; Recombinant Fusion Proteins; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tetrahydronaphthalenes	2008
Novel therapies for cutaneous T-cell lymphomas. Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 5 Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2008
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. Journal of the American Academy of Dermatology, 2010, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Bexarotene; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Humans; Lymphoma, T-Cell, Cutaneous; Male; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2010
Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Advances in dermatology, 2002, Volume: 18 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cytokines; Diphtheria Toxin; Humans; Immunotherapy; Interferon Type I; Interferon-gamma; Interleukin-12; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Photopheresis; Recombinant Fusion Proteins; Recombinant Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2002
Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clinical lymphoma, 2003, Volume: 3, Issue:4 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin	2003
Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. Journal of drugs in dermatology : JDD, 2003, Volume: 2, Issue:2 Topics: Administration, Topical; Bexarotene; Gels; Humans; Lymphoma, T-Cell, Cutaneous; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2003
Bexarotene: a clinical review. Expert review of anticancer therapy, 2004, Volume: 4, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Humans; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Neoplasms; Skin Neoplasms; Tetrahydronaphthalenes	2004
Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Seminars in oncology, 2006, Volume: 33, Issue:1 Suppl 3 Topics: Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Humans; Lymphoma, T-Cell, Cutaneous; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2006
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. The British journal of dermatology, 2006, Volume: 155, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2006
Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl 1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cytokines; Diphtheria Toxin; Humans; Immunologic Factors; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Neoplasm Staging; Purines; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2007
Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Combined Modality Therapy; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Neoplasm Staging; Photopheresis; PUVA Therapy; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2007
The optimal use of bexarotene in cutaneous T-cell lymphoma. The British journal of dermatology, 2007, Volume: 157, Issue:3 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; PUVA Therapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:16 Topics: Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Staging; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approval; Humans; Hydroxamic Acids; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2007
Current treatment of Cutaneous T-Cell Lymphoma. Dermatology online journal, 2001, Volume: 7, Issue:1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biopsy; Carmustine; Disease Progression; Drug Eruptions; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Neoplasm Staging; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Tetrahydronaphthalenes; Vitamin D	2001
Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2001, Volume: 15, Issue:7 Topics: Bexarotene; Diphtheria Toxin; Humans; Immunologic Factors; Interferon-alpha; Interleukin-12; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Photopheresis; Phototherapy; Proteins; Recombinant Fusion Proteins; Tetrahydronaphthalenes	2001
Oral bexarotene in the treatment of cutaneous T-cell lymphoma. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:9 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Tetrahydronaphthalenes	2001
The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Bexarotene; Humans; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes	2000
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Diphtheria Toxin; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Immunotoxins; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2000

Trials

12 trial(s) available for bexarotene and Lymphoma, T-Cell, Cutaneous

Article	Year
Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. The Journal of dermatology, 2020, Volume: 47, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bexarotene; Disease Progression; Female; Heart Failure; Humans; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; PUVA Therapy; Sepsis; Severity of Illness Index; Skin Neoplasms; Treatment Outcome	2020
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United Kingdom	2013
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Disease-Free Survival; Doxorubicin; Female; Humans; Injections; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Polyethylene Glycols; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2014
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia & lymphoma, 2012, Volume: 53, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Cell Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Retinoic Acid; Retinoid X Receptors; Tetrahydronaphthalenes; Transcription, Genetic; Vorinostat	2012
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:5 Topics: Administration, Topical; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2003
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Retinoic Acid; Retinoid X Receptors; Retrospective Studies; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin	2004
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood, 2005, Jul-15, Volume: 106, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Drug Tolerance; Female; Humans; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Fusion Proteins; Recurrence; Skin Neoplasms; Tetrahydronaphthalenes; Up-Regulation	2005
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:4 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Risk Assessment; Rosiglitazone; Single-Blind Method; Survival Analysis; Tetrahydronaphthalenes; Thiazolidinediones; Treatment Outcome	2007
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer, 2007, May-01, Volume: 109, Issue:9 Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2007
Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. The Australasian journal of dermatology, 2001, Volume: 42, Issue:2 Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Australia; Bexarotene; Capsules; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gels; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Prognosis; Remission Induction; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2001
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Quality of Life; Tetrahydronaphthalenes	2001
The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Bexarotene; Humans; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes	2000

Other Studies

64 other study(ies) available for bexarotene and Lymphoma, T-Cell, Cutaneous

Article	Year
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2- Journal of medicinal chemistry, 2016, 10-13, Volume: 59, Issue:19 Topics: Antineoplastic Agents; Bexarotene; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histone Deacetylase 1; Humans; Lymphoma, T-Cell, Cutaneous; Models, Molecular; Niacin; Retinoid X Receptors; Sterol Regulatory Element Binding Proteins; Tetrahydronaphthalenes	2016
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:3 Topics: Bexarotene; Electrons; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome	2022
Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses. Acta dermato-venereologica, 2022, 07-07, Volume: 102 Topics: Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; T-Lymphocytes	2022
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Humans; Integrin alphaVbeta3; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2022
Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. The British journal of dermatology, 2022, Volume: 187, Issue:6 Topics: Acitretin; Anticarcinogenic Agents; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplasms; Tetrahydronaphthalenes	2022
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:21 Topics: Adult; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms	2022
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene. International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24 Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides	2022
CD4/CD8 double-negative T-cell lymphoma successfully treated with a combination of bexarotene and total skin electron beam therapy. The Journal of dermatology, 2023, Volume: 50, Issue:7 Topics: Bexarotene; CD8-Positive T-Lymphocytes; Electrons; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms	2023
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Advances in therapy, 2023, Volume: 40, Issue:5 Topics: Bexarotene; Brentuximab Vedotin; Canada; Cost-Benefit Analysis; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Methotrexate; Neoplasm Recurrence, Local; Physicians; Skin Neoplasms	2023
Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas. Cells, 2023, Nov-04, Volume: 12, Issue:21 Topics: Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes	2023
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. The Journal of dermatology, 2020, Volume: 47, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Chemoradiotherapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Japan; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Severity of Illness Index; Skin Neoplasms; Ultraviolet Therapy	2020
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. Endocrine journal, 2022, Jan-28, Volume: 69, Issue:1 Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplasms; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine	2022
Alitretinoin in the treatment of cutaneous T-cell lymphoma. Cancer medicine, 2021, Volume: 10, Issue:20 Topics: Adult; Aged; Alitretinoin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Sezary Syndrome; Skin Neoplasms	2021
Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient. Cutis, 2017, Volume: 99, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; CD4-Positive T-Lymphocytes; Humans; Lymphoma, T-Cell, Cutaneous; Lymphopenia; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2017
RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines. Experimental dermatology, 2017, Volume: 26, Issue:11 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Benzoates; Bexarotene; Cell Adhesion; Cell Line; Cell Movement; Cell Proliferation; Gene Expression; Humans; Integrin beta Chains; Lymphoma, T-Cell, Cutaneous; Retinoic Acid Receptor alpha; Retinoid X Receptors; RNA, Messenger; Tetrahydronaphthalenes; Tretinoin	2017
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. The Journal of dermatological treatment, 2018, Volume: 29, Issue:5 Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Methotrexate; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2018
The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. Journal of dermatological science, 2018, Volume: 90, Issue:3 Topics: Adolescent; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Bexarotene; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Evaluation, Preclinical; Fatty Acids, Unsaturated; Humans; Inhibitory Concentration 50; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Naphthalenes; Proteasome Endopeptidase Complex; Retinoid X Receptors; S-Phase Kinase-Associated Proteins; Signal Transduction; Tetrahydronaphthalenes	2018
Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. JAMA dermatology, 2018, 12-01, Volume: 154, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apolipoprotein A-V; Apolipoprotein C-III; Bexarotene; DNA; Female; Follow-Up Studies; Genotype; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index	2018
Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:10 Topics: Bexarotene; Doxorubicin; Humans; Liposomes; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Pilot Projects	2019
Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retrospective Studies; Tetrahydronaphthalenes; Young Adult	2013
Papuloerythroderma of Ofuji associated with CD3,(+) CD4,(+) and CD8(-) cutaneous T-cell lymphoma and monoclonal gammopathy of undetermined significance. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:5 Topics: Bexarotene; CD3 Complex; CD4 Antigens; Eosinophilia; Folliculitis; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; PUVA Therapy; Remission Induction; Skin Diseases, Vesiculobullous; Skin Neoplasms; T-Lymphocyte Subsets; Tetrahydronaphthalenes	2015
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment. The American Journal of dermatopathology, 2016, Volume: 38, Issue:11 Topics: Aged; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Depsipeptides; Disease Progression; Drug Substitution; Fatal Outcome; Humans; Immunohistochemistry; Immunophenotyping; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Metastasis; Phenotype; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2016
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clinical and experimental dermatology, 2017, Volume: 42, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipid Metabolism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes	2017
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. The Journal of dermatological treatment, 2009, Volume: 20, Issue:3 Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Retrospective Studies; Risk Assessment; Sex Factors; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2009
Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. The British journal of dermatology, 2009, Volume: 160, Issue:3 Topics: Anticarcinogenic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bexarotene; Cell Cycle; Cell Cycle Proteins; Cell Survival; DNA-Binding Proteins; Humans; Lymphoma, T-Cell, Cutaneous; Neoplastic Stem Cells; Nuclear Proteins; Protein Serine-Threonine Kinases; Signal Transduction; Skin Neoplasms; Tetrahydronaphthalenes; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2009
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. British journal of haematology, 2009, Volume: 145, Issue:1 Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood. Journal of cutaneous pathology, 2009, Volume: 36, Issue:5 Topics: Adolescent; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Foreign Bodies; Giant Cells; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2009
About the cutaneous targets of bexarotene in CTCL patients. Experimental dermatology, 2010, Volume: 19, Issue:8 Topics: Aged; Anticarcinogenic Agents; Antigens, CD1; Apoptosis; Bexarotene; Biopsy; Case-Control Studies; Female; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Keratinocytes; Langerhans Cells; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes	2010
Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Experimental dermatology, 2010, Volume: 19, Issue:8 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; T-Lymphocytes, Regulatory; Tetrahydronaphthalenes; Transforming Growth Factor beta1	2010
Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Phototherapy; Retrospective Studies; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes; Treatment Outcome	2010
A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. Journal of cutaneous pathology, 2010, Volume: 37, Issue:11 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Epidermolysis Bullosa Simplex; Female; Heterozygote; Humans; Keratin-5; Lymphoma, T-Cell, Cutaneous; Phenotype; Tetrahydronaphthalenes	2010
Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. Acta dermato-venereologica, 2011, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Cells, Cultured; Chromosomes, Human, Pair 12; Finland; Gene Deletion; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lymphoma, T-Cell, Cutaneous; Membrane Proteins; Nerve Tissue Proteins; Patient Selection; Pharmacogenetics; Precision Medicine; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Tetraploidy; Time Factors; Treatment Outcome	2011
[Therapeutic perspectives of cutaneous T-cell lymphoma]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5 Suppl 2 Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Interferons; Lymphoma, T-Cell, Cutaneous; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes	2011
Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transplant immunology, 2011, Volume: 25, Issue:2-3 Topics: Adult; Bexarotene; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphocyte Transfusion; Lymphoma, T-Cell, Cutaneous; Male; Photopheresis; PUVA Therapy; Recurrence; Skin Neoplasms; Tetrahydronaphthalenes	2011
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Diabetes Mellitus, Type 1; Disease-Free Survival; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Panniculitis; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult	2012
Cutaneous T-cell lymphoma's confounding nature. Journal of the National Cancer Institute, 2012, Jun-06, Volume: 104, Issue:11 Topics: Aged; Alemtuzumab; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brentuximab Vedotin; Delayed Diagnosis; Diagnosis, Differential; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Remission Induction; Sezary Syndrome; Stem Cell Transplantation; Tetrahydronaphthalenes; Transplantation, Homologous	2012
Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta dermato-venereologica, 2012, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticarcinogenic Agents; Aspartate Aminotransferases; Bexarotene; Combined Modality Therapy; Finland; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Liver; Lymphoma, T-Cell, Cutaneous; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Skin Neoplasms; Tetrahydronaphthalenes	2012
Acitretin for the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:2 Topics: Acitretin; Adult; Aged; Aged, 80 and over; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene). ChemMedChem, 2012, Volume: 7, Issue:9 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Line, Tumor; Halogenation; Humans; Lymphoma, T-Cell, Cutaneous; Molecular Docking Simulation; Neoplasms; Protein Multimerization; Retinoid X Receptors; Tetrahydronaphthalenes	2012
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. The British journal of dermatology, 2013, Volume: 168, Issue:1 Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, HDL; Clinical Protocols; Drug Administration Schedule; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver Function Tests; Lymphoma, T-Cell, Cutaneous; Musculoskeletal Pain; Pancreatitis; Pregnancy; Pregnancy Complications; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin; Thyroxine	2013
Combination treatment in CTCL: the current role of bexarotene. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2012, Volume: 147, Issue:6 Topics: Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Humans; Italy; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes	2012
Topical targretin and intralesional interferon alfa for cutaneous lymphoma of the scalp. Archives of dermatology, 2002, Volume: 138, Issue:11 Topics: Administration, Topical; Bexarotene; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Intralesional; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Scalp Dermatoses; Severity of Illness Index; Tetrahydronaphthalenes; Treatment Outcome	2002
Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:6 Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Follow-Up Studies; Humans; Immunohistochemistry; Immunologic Factors; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy	2002
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:3 Topics: Antineoplastic Agents; Bexarotene; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lymphocyte Activation; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; T-Lymphocytes; Tetrahydronaphthalenes	2004
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; PUVA Therapy; Retrospective Studies; Tetrahydronaphthalenes	2004
Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks. Gene expression, 2005, Volume: 12, Issue:3 Topics: Animals; Apolipoproteins; Bexarotene; Blotting, Northern; Cell Nucleus; Cluster Analysis; Dimerization; Fenofibrate; Gene Expression Regulation; Genotype; Hypolipidemic Agents; Kidney; Liver; Lymphoma, T-Cell, Cutaneous; Male; Mice; Mice, Inbred C57BL; Models, Genetic; Models, Statistical; Oligonucleotide Array Sequence Analysis; PPAR alpha; Principal Component Analysis; Retinoid X Receptor alpha; Retinoids; RNA; Signal Transduction; Tetrahydronaphthalenes; Time Factors; Tissue Distribution; Transcription, Genetic; Triglycerides; Vitamin D	2005
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:10 Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine	2003
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. The Journal of investigative dermatology, 2006, Volume: 126, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Female; Humans; Interleukin-2; Ki-1 Antigen; L-Lactate Dehydrogenase; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Receptors, Interleukin-2; Recombinant Fusion Proteins; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2006
[Treatment of cutaneous T-cell lymphomas with bexarotene]. Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:10 Topics: Adult; Aged; Algorithms; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes	2005
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. The British journal of dermatology, 2006, Volume: 154, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Diphtheria Toxin; Fatal Outcome; Humans; Interleukin-2; Killer Cells, Natural; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2006
Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma. Acta dermato-venereologica, 2006, Volume: 86, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Female; Humans; Interferons; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Neoplasm Metastasis; Skin Neoplasms; Tetrahydronaphthalenes	2006
Bexarotene and systemic disease progression in CTCL? Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:2 Topics: Antineoplastic Agents; Bexarotene; Disease Progression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Reproducibility of Results; Risk Factors; Sezary Syndrome; Tetrahydronaphthalenes	2006
Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Archives of dermatology, 2007, Volume: 143, Issue:5 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Health Status; Health Status Indicators; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Photopheresis; Pilot Projects; Quality of Life; Skin Neoplasms; Tetrahydronaphthalenes	2007
[Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders]. Anales de medicina interna (Madrid, Spain : 1984), 2007, Volume: 24, Issue:12 Topics: Anticarcinogenic Agents; Bexarotene; Dyslipidemias; Female; Humans; Hypothyroidism; Ligands; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retinoid X Receptors; Skin Neoplasms; Tetrahydronaphthalenes	2007
Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Antineoplastic Agents; Bexarotene; Humans; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors	2008
Bexarotene monotherapy for epidermotropic CD8+ CTCL. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; CD8 Antigens; Humans; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms; Tetrahydronaphthalenes	2008
Central hypothyroidism associated with retinoid X receptor-selective ligands. The New England journal of medicine, 1999, Apr-08, Volume: 340, Issue:14 Topics: Aged; Bexarotene; Cohort Studies; Humans; Hypothyroidism; Ligands; Lymphoma, T-Cell, Cutaneous; Male; Promoter Regions, Genetic; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Thyroid Function Tests; Thyroid Gland; Thyrotropin; Transcription Factors	1999
From the Food and Drug Administration. JAMA, 2000, Mar-01, Volume: 283, Issue:9 Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bexarotene; Celecoxib; Cisapride; Contraindications; Cyclooxygenase Inhibitors; Drug Labeling; Gastrointestinal Agents; Humans; Lymphoma, T-Cell, Cutaneous; Pyrazoles; Receptors, Retinoic Acid; Sulfonamides; Tetrahydronaphthalenes	2000
Bexarotene (Targretin) for cutaneous T-cell lymphoma. The Medical letter on drugs and therapeutics, 2000, Apr-03, Volume: 42, Issue:1075 Topics: Bexarotene; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Fees, Pharmaceutical; Half-Life; Humans; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Receptors, Retinoic Acid; Retinoids; Tetrahydronaphthalenes	2000
Bexarotene. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Dec-01, Volume: 57, Issue:23 Topics: Antineoplastic Agents; Bexarotene; Drug Interactions; Humans; Lymphoma, T-Cell, Cutaneous; Tetrahydronaphthalenes	2000
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. The oncologist, 2001, Volume: 6, Issue:1 Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration	2001
Two novel therapies for the treatment of cutaneous T-cell lymphoma. Clinical lymphoma, 2000, Volume: 1 Suppl 1 Topics: Anticarcinogenic Agents; Bexarotene; Diphtheria Toxin; Humans; Immunosuppressive Agents; Immunotoxins; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes	2000
Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. Journal of the American Academy of Dermatology, 2001, Volume: 45, Issue:6 Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Drug Therapy, Combination; Humans; Interferon-alpha; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms; Tetrahydronaphthalenes	2001
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Annexin A5; Apoptosis; Bexarotene; Blotting, Western; Cell Cycle; Cell Survival; Chromosomal Proteins, Non-Histone; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, T-Cell, Cutaneous; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Binding; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptors; Skin Neoplasms; Survivin; Tetrahydronaphthalenes; Time Factors; Transcription Factors; Tumor Cells, Cultured	2002